Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too

Executive Summary

The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.

You may also be interested in...



Sanofi Pasteur Head Loew On The Vaccine Unit's Future Growth Drivers

David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Regeneron Phase III Stumble Shows RSV Market Is No Child's Play

Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel